Opportunities in Real-World Evidence, Improved Data for Quality of Care

January 30, 2018
Members of CancerLinQ's Oncology Leadership Council meet at ASCO headquarters in Alexandria, Va. on Jan. 26.

On Jan. 26, the CancerLinQ Oncology Leadership Council (OLC) convened leaders from its full coalition of public, private, and not-for-profit partners in an all-day summit to discuss CancerLinQ®—its inception, current status, and its strategic plans for the next year and beyond.

The CancerLinQ OLC was formed by CancerLinQ LLC to advise and provide its leadership and staff with expertise, experience, and perspectives from these diverse external stakeholders. Additionally, the OLC is designed to drive collaboration, inclusion, and transparency across the cancer care ecosystem.

As CancerLinQ LLC Chief Executive Officer (CEO) Kevin Fitzpatrick stated to those assembled, “We need the collective wisdom of individuals in this room for CancerLinQ to reach its full potential. You represent the leading edge of CancerLinQ’s vision, to improve the quality and value of care for all patients with cancer.”

Attendees included the OLC representative(s) from each of CancerLinQ LLC’s corporate, nonprofit, and government collaborators:

  • American Academy of PAs (AAPA): Heather M. Hylton, MS, PA-C, DFAAPA, Director of Physician Assistant Services, Department of Medicine at Memorial Sloan Kettering Cancer Center
  • American College of Medical Genetics and Genomics (ACMG): Peter J. Hulick, MD, MMSc, FACMG, Medical Director of the Center for Personalized Medicine and Center for Medical Genetics at NorthShore University HealthSystem and Clinical Assistant Professor in the Department of Human Genetics at the University of Chicago Pritzker School of Medicine
  • Association for Molecular Pathology (AMP): Federico A. Monzon, MD, FCAP, AMP Past President and Chief Medical Officer of Castle Biosciences
  • American Society for Radiation Oncology (ASTRO): Sameer R. Keole, MD, OLC Chair, CancerLinQ Board of Governors member and Assistant Professor of Radiation Oncology at the Mayo Clinic
  • AstraZeneca: Delphine Moreau, MD, Oncology TA Vice President, Global Medical Affairs, and Robert White, PhD, Director of Real-World Evidence Alliance and Strategy
  • College of American Pathologists (CAP): Mary E. Edgerton, MD, PhD, Associate Professor, Department of Pathology at University of Texas MD Anderson Cancer Center and Adjunct Associate Professor, School of Biomedical Informatics at University of Texas Health Science Center at Houston
  • Cancer Informatics for Cancer Centers (CI4CC): Sorena Nadaf, MS, MMI, CI4CC Co-Founder and Chief Informatics Officer, Senior Vice President, and Director of Digital Health Innovation and Data Science at City of Hope
  • DIA (Drug Information Association): Tshaka Cunningham, PhD, Associate Director for Scientific Collaborations
  • Food and Drug Administration (FDA): Sean Khozin, MD, MPH, acting associate director in the FDA’s Oncology Center of Excellence and Founder and Director of the FDA’s Information Exchange and Data Transformation (INFORMED) initiative
  • Hematology/Oncology Pharmacy Association (HOPA): Amy Hatfield Seung, PharmD, BCOP, Senior Director of Clinical Development at Assist Rx
  • National Cancer Institute (NCI): Lynne Penberthy, MD, MPH, Associate Director for the Surveillance Research Program of the National Cancer Institute
  • National Society of Genetic Counselors (NSGC): Joy Larsen Haidle, MS, LGC, NSGC Past President and Genetic Counselor at North Memorial Health Cancer Center
  • Oncology Nursing Society (ONS): Michele Galioto, MSN, RN, Assistant Chief Clinical Officer at ONS
  • Precision HealthAI: Brigham Hyde, PhD, CEO, and David Dornstreich, Senior Vice President of Business Development
  • Society of Gynecologic Oncology (SGO): Summer Dewdney, MD, Assistant Professor of Gynecologic Oncology at Rush University Medical Center in Chicago, and SGO Past President Richard R. Barakat, MD, MBA, Director, Regional Care Network and Vice Chair, Regional Care Network and Affiliations in the Department of Surgery at Memorial Sloan Kettering Cancer Center
  • Tempus: Ryan Fukushima, MBA, Chief Operating Officer, and Richard M. Ross, MSMIT, Vice President of Business Development.

Currently, the CancerLinQ database—ASCO’s health information technology platform aimed at improving the quality of cancer care using real-world cancer data—has more than 130 participating practices in 40 states and the District of Columbia.

The CancerLinQ OLC will next meet during ASCO’s Annual Meeting in Chicago, June 1–5, 2018.